MX2022013770A - Relaxinas modificadas y metodos de uso de las mismas. - Google Patents

Relaxinas modificadas y metodos de uso de las mismas.

Info

Publication number
MX2022013770A
MX2022013770A MX2022013770A MX2022013770A MX2022013770A MX 2022013770 A MX2022013770 A MX 2022013770A MX 2022013770 A MX2022013770 A MX 2022013770A MX 2022013770 A MX2022013770 A MX 2022013770A MX 2022013770 A MX2022013770 A MX 2022013770A
Authority
MX
Mexico
Prior art keywords
methods
relaxins
engineered
compositions
relaxin
Prior art date
Application number
MX2022013770A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Kruse
Sarah Cecilia Erlandson
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of MX2022013770A publication Critical patent/MX2022013770A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/64Relaxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2221Relaxins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2022013770A 2020-05-08 2021-05-07 Relaxinas modificadas y metodos de uso de las mismas. MX2022013770A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063021814P 2020-05-08 2020-05-08
PCT/US2021/031260 WO2021226439A2 (en) 2020-05-08 2021-05-07 Engineered relaxins and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022013770A true MX2022013770A (es) 2023-04-03

Family

ID=78468429

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013770A MX2022013770A (es) 2020-05-08 2021-05-07 Relaxinas modificadas y metodos de uso de las mismas.

Country Status (10)

Country Link
US (1) US20230174610A1 (https=)
EP (1) EP4146681A4 (https=)
JP (1) JP2023524981A (https=)
KR (1) KR20230008791A (https=)
CN (1) CN115768801A (https=)
AU (1) AU2021268355A1 (https=)
CA (1) CA3180662A1 (https=)
IL (1) IL297951A (https=)
MX (1) MX2022013770A (https=)
WO (1) WO2021226439A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118510536A (zh) 2021-11-11 2024-08-16 泰克托尼治疗股份有限公司 松弛素-2融合蛋白类似物及其使用方法
AU2022410335A1 (en) * 2021-12-15 2024-07-18 Medimmune Limited Treatment using heterodimeric relaxin fusions
AU2024270919A1 (en) * 2023-05-18 2026-01-15 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835251A (en) * 1986-06-23 1989-05-30 Genetech, Inc. Method of chain combination
US20110243943A1 (en) * 2010-04-02 2011-10-06 Athena Discovery, Inc. Treatment using relaxin-fusion proteins with extended in vivo half-lives
US9567386B2 (en) * 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
RU2014103288A (ru) * 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
JP6822839B2 (ja) * 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
IL263079B2 (en) * 2016-05-18 2024-05-01 Modernatx Inc Polynucleotides encoding relaxin
EP3574004A1 (en) * 2017-01-25 2019-12-04 Medimmune, LLC Relaxin fusion polypeptides and uses thereof
PE20191716A1 (es) * 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos

Also Published As

Publication number Publication date
IL297951A (en) 2023-01-01
WO2021226439A2 (en) 2021-11-11
CN115768801A (zh) 2023-03-07
CA3180662A1 (en) 2021-11-11
KR20230008791A (ko) 2023-01-16
EP4146681A2 (en) 2023-03-15
WO2021226439A8 (en) 2021-12-23
WO2021226439A3 (en) 2022-02-10
US20230174610A1 (en) 2023-06-08
JP2023524981A (ja) 2023-06-14
EP4146681A4 (en) 2024-06-26
AU2021268355A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
PH12022551750A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2022013770A (es) Relaxinas modificadas y metodos de uso de las mismas.
MX2022010425A (es) Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.
MX2025003987A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos
MY209609A (en) Immunomodulators, compositions and methods thereof
PH12022500003A1 (en) Il-2 conjugates and methods of use to treat autoimmune diseases
MX2022000397A (es) Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
JOP20230036A1 (ar) نواهض مستقبل أوريكسين بيروليدين سيكلوهيبتان
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2024001243A (es) Composiciones y metodos para el tratamiento de melanoma.
PH12022552738A1 (en) Compositions comprising nanoparticles, method of making and uses thereof
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
PH12022552371A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2024006064A (es) Composicion cristalina de tildacerfont y metodos de uso y preparacion de la misma.
MX2022011163A (es) Conjugados de polipeptidos de interleucina-2 y sus usos.
NZ754676A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
SA521430793B1 (ar) أجسام مضادة مضادة لسيما 3أ واستخداماتها في علاج أمراض العين أو البصر
WO2023114847A3 (en) Compositions and methods for treating disease
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
MX2022016501A (es) Formulaciones no porcinas y metodos de estas.
PH12022550277A1 (en) Biopharmacuetical compositions and related methods
MX2025013717A (es) Inhibidores de ciclina
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases
MX2023014984A (es) Anticuerpos anti-csp.